A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer
NCT ID: NCT05208268
Last Updated: 2022-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
676 participants
OBSERVATIONAL
2020-07-23
2022-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
NCT00960869
A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin
NCT00441519
A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers
NCT00961350
Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin
NCT01069939
Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control
NCT00713947
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pariet
Participants with gastric and duodenal ulcer being administered with Pariet 5 mg, tablet within the scope of the approved label for Korea under the medical judgment of the investigator will be observed up to maximum of 24 weeks.
Pariet
Pariet Tablets.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pariet
Pariet Tablets.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participants who have a history of gastric and duodenal ulcer falling under the approved indication for Pariet Tablet 5 mg and who are receiving Pariet Tablet 5 mg to prevent gastric and duodenal ulcer from low dose aspirin use of 100 mg or less daily
3. Participants whose prescription of Pariet Tablet 5 mg has been determined before study participation
4. Participants who have given written consent to the use of their personal and medical information
Exclusion Criteria
2. Participants administered with atazanavir
3. Pregnant or lactating
4. Participants administered with rilpivirine
5. Participants currently participating in other clinical trials
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Korea Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site #09
Bucheon-si, Gyeongji-do, South Korea
Site #31
Bucheon-si, Gyeongji-do, South Korea
Site #24
Dongtan, Gyeongji-do, South Korea
Site #03
Ilsan, Gyeongji-do, South Korea
Site #11
Ilsan, Gyeongji-do, South Korea
Site #17
Incheon, Gyeongji-do, South Korea
Site #20
Changwon, Gyeongsangnam-do, South Korea
Site #29
Iksan, Jeollabuk-do, South Korea
Site #19
Cheongju-si, North Chungcheong, South Korea
Site #01
Chungju, North Chungcheong, South Korea
Site #07
Busan, , South Korea
Site #08
Busan, , South Korea
Site #14
Busan, , South Korea
Site #15
Busan, , South Korea
Site #28
Busan, , South Korea
Site #02
Daegu, , South Korea
Site #23
Daegu, , South Korea
Site #27
Daegu, , South Korea
Site #05
Seoul, , South Korea
Site #06
Seoul, , South Korea
Site #10
Seoul, , South Korea
Site #13
Seoul, , South Korea
Site #16
Seoul, , South Korea
Site #18
Seoul, , South Korea
Site #21
Seoul, , South Korea
Site #22
Seoul, , South Korea
Site #25
Seoul, , South Korea
Site #26
Seoul, , South Korea
Site #30
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E3810-M082-520
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.